Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,254 | 0,284 | 13:41 | |
0,262 | 0,274 | 13:34 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | IGC Pharma, Inc.: IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting | 176 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / May 12, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it presented its latest scientific poster, titled "Genetic Toxicity... ► Artikel lesen | |
24.04. | IGC Pharma, Inc.: IGC Pharma Welcomes Strategic Investment from Advisors | 225 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / April 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company's recently appointed advisors entered into a Share... ► Artikel lesen | |
21.04. | IGC Pharma, Inc.: IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs | 252 | ACCESS Newswire | Industry Veterans Bring Deep Strategic Experience to Guide Alzheimer's Clinical Expansion and Commercial Strategy POTOMAC, MARYLAND / ACCESS Newswire / April 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC)... ► Artikel lesen | |
08.04. | IGC Pharma, Inc.: IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program | 287 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial with... ► Artikel lesen | |
01.04. | IGC Pharma, Inc.: IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health | 253 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation... ► Artikel lesen | |
26.03. | IGC Pharma, Inc.: IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances | 352 | ACCESS Newswire | - IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's - POTOMAC, MD / ACCESS Newswire / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company")... ► Artikel lesen | |
20.03. | IGC Pharma, Inc.: IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences | 233 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the... ► Artikel lesen | |
IGC PHARMA Aktie jetzt für 0€ handeln | |||||
17.03. | IGC Pharma, Inc.: IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida | 244 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / March 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's... ► Artikel lesen | |
12.03. | IGC Pharma, Inc.: IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" | 176 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / March 12, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage report... ► Artikel lesen | |
10.03. | IGC Pharma, Inc.: IGC Pharma Announces Equity Analyst Update by Alliance Global Partners about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" | 218 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / March 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update... ► Artikel lesen | |
06.03. | IGC Pharma, Inc. (IGC) Advances AI Model to Enhance Alzheimer's Diagnosis | 1 | Insider Monkey | ||
04.03. | IGC Pharma, Inc.: IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection | 249 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development... ► Artikel lesen | |
20.02. | IGC Pharma, Inc.: IGC Pharma Expands Holiby Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market | 135 | ACCESS Newswire | - New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function - POTOMAC, MD / ACCESS Newswire / February 20, 2025 / IGC Pharma, Inc. (NYSE American:IGC)... ► Artikel lesen | |
18.02. | IGC Pharma GAAP EPS of -$0.02, revenue of $257M | 1 | Seeking Alpha | ||
18.02. | IGC Pharma, Inc.: IGC Pharma Reports Third Quarter Fiscal 2025 Results | 305 | ACCESS Newswire | POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended... ► Artikel lesen | |
11.02. | IGC Pharma, Inc.: IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby | 272 | ACCESS Newswire | - Product Launch Leverages IGC's State-Of-The-Art Manufacturing Facility To Support Revenue-Generating Brand for Immunity & Energy - POTOMAC, MD / ACCESS Newswire / February 11, 2025 / IGC Pharma, Inc.... ► Artikel lesen | |
28.01. | IGC Pharma, Inc.: IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease | 318 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / January 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is proud to announce its selection as one of the top 15 finalists in the PREPARE... ► Artikel lesen | |
21.01. | IGC Pharma, Inc.: IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor | 525 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of... ► Artikel lesen | |
13.01. | IGC Pharma, Inc.: IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets | 287 | ACCESS Newswire | POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside... ► Artikel lesen | |
08.01. | IGC Pharma, Inc.: IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy | 330 | ACCESS Newswire | Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 22,545 | +1,69 % | UBS stuft BAYER AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Bayer auf "Neutral" mit einem Kursziel von 22 Euro belassen. Bei der Quartalszahlenvorlage am 13. Mai dürfte der Fokus auf Fortschritten bei... ► Artikel lesen | |
NOVO NORDISK | 58,45 | +0,95 % | Amazon, Deutsche Telekom, Deutz, Novo Nordisk, Rheinmetall, Smartbroker - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
PFIZER | 19,788 | +0,51 % | Dividendenbekanntmachungen (09.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AAK AB SE0011337708 5 SEK 0,4573 EUR ADDLIFE AB SE0014401378 0,75 SEK 0,0686 EUR ALLIANZ SE DE0008404005 - 15,4 EUR ALZCHEM GROUP... ► Artikel lesen | |
NOVARTIS | 96,03 | +1,31 % | AKTIEN IM FOKUS: Kursrutsch bei Pharmawerten - Trump setzt Branche unter Druck | ZÜRICH/LONDON/PARIS (dpa-AFX) - Aktien aus dem Pharmasektor sind am Montag schwer unter Druck geraten wegen Sorgen um die Profitabilität im US-Geschäft. US-Präsident Donald Trump will die Preise für... ► Artikel lesen | |
MERCK KGAA | 117,20 | -5,37 % | BARCLAYS stuft MERCK KGAA auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Merck KGaA von 195 auf 160 Euro gesenkt, aber die Einstufung auf "Overweight" belassen. Der nun verantwortliche... ► Artikel lesen | |
GILEAD SCIENCES | 89,04 | +1,12 % | Gilead Sciences-Aktie: Trump als Kurs-Killer | Die US-Börsen feiern zum Wochenbeginn die Deeskalation im Handelskonflikt zwischen den USA und China. Aber Pharmawerte wie die Gilead Sciences-Aktie gehören zu den Verlierern in diesem sehr positiven... ► Artikel lesen | |
AURORA CANNABIS | 4,560 | +1,00 % | BRISANTE Meldung setzt Aurora Cannabis Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
SANOFI | 89,27 | +0,50 % | Dividendenbekanntmachungen (12.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AKER BP ASA NO0010345853 6,5173 NOK 0,5586 EUR ALEXANDERS INC US0147521092 4,5 USD 4,0005 EUR AMG CRITICAL MATERIALS NV NL0000888691 0... ► Artikel lesen | |
ABBVIE | 159,60 | +0,38 % | Aktien New York Ausblick: Zolleinigung bringt neuen Schwung - Pharma schwach | NEW YORK (dpa-AFX) - Eine Einigung im Zollstreit zwischen den USA und China beflügelt am Montag die New Yorker Börsen. Die beiden größten Volkswirtschaften der Welt kappen die gegenseitig verhängten... ► Artikel lesen | |
CANOPY GROWTH | 1,258 | -0,32 % | Starke Zahlen, Aktie steigt: Nicht Canopy Growth: Diese Cannabis-Aktie gibt es jetzt umsonst! | © Foto: Dall-EDas Cannabisunternehmen Cronos hat am Donnerstagmittag starke Quartalszahlen vorgelegt - und im Unterschied zu Canopy Growth einen Nettogewinn erzielt.Innerhalb der Cannabis-Branche gilt... ► Artikel lesen | |
ELI LILLY | 645,00 | -0,45 % | Eli Lilly und Co in der Krise: Entscheidet sich nächste Woche die Zukunft der Pharma-Aktien? | Schon in der nächsten Woche könnte sich viel bei Pharma-Aktien wie Eli Lilly oder Pfizer im Chart verändern. Grund sind neue US-Zölle. Die Pharmabranche ist ein wichtiger Bestandteil der Wall Street... ► Artikel lesen | |
MERCK & CO | 66,50 | +1,06 % | Merck says late-stage trial for Keytruda regimen hit main goal in ovarian cancer | ||
ASTRAZENECA | 121,15 | +1,72 % | AstraZeneca, Bristol-Myers, GSK, Merck, Novartis, Pfizer und Sanofi weniger von Trumps Preisgestaltung betroffen | ||
TILRAY BRANDS | 0,395 | +0,53 % | Tilray Brands, Inc.: Shock Top: A Bold Rebrand for a Craft Beer Icon | PORTLAND, Ore., May 08, 2025 (GLOBE NEWSWIRE) -- Shock Top, a craft beer icon and brand by Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY), known for its bold flavors and unfiltered wheat... ► Artikel lesen | |
BRISTOL-MYERS SQUIBB | 39,705 | +0,53 % | Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii's Plavix Lawsuit |